Subject
Clinical Biochemistry,General Medicine
Reference12 articles.
1. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam;Wooley;Antimicrob. Agents Chemother.,2014
2. Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency;Kampf;Antimicrob. Agents Chemother.,1981
3. KDIGO, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, (n.d.). https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.
4. P. Delanaye, F. Guerber, A. Scheen, T. Ellam, A. Bouquegneau, D. Guergour, C. Mariat, H. Pottel, Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies, Clin Pharmacokinet. 56 (2017) 193–205. 10.1007/s40262-016-0434-z.
5. Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation—SFAR)